| 2015 | | Oral Maintenance Chemotherapy with 6-Mercaptopurine and Methotrexate in Patients with Acute Myeloid Leukemia Ineligible for Transplantation. | 강석윤, 박준성, 안미선, 이현우, 정성현, 최용원, 최진혁 |
| 2020 | | Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09) | 안미선 |
| 1996 | | Overexpression of c-ErbB-2 protein in gastric cancer by immunohistochemical stain. | 최진혁 |
| 2019 | | Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial | 강석윤 |
| 2012 | | Pathologic diagnosis of recurrent glioblastoma: morphologic, immunohistochemical, and molecular analysis of 20 paired cases | 김보영, 김세혁, 김영배, 김장희, 신승수, 이기범, 이현우, 정선용, 한재호 |
| 2014 | | Patterns of neutropenia and risk factors for febrile neutropenia of diffuse large B-cell lymphoma patients treated with rituximab-CHOP. | 강석윤, 박준성, 안미선, 이현우, 정성현, 최용원, 최진혁 |
| 2019 | | PD-L1 protein expression in non-small-cell lung cancer and its relationship with the hypoxia-related signaling pathways: A study based on immunohistochemistry and RNA sequencing data | 고영화, 이수진, 이현우, 정준호, 한재호, 함석진 |
| 2020 | | Phase II study of durvalumab and tremelimumab in pulmonary sarcomatoid carcinoma: KCSG-LU16-07 | 안미선 |
| 2019 | | Phase II study of R-CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: consortium for improving survival of lymphoma (CISL) study | 정성현 |
| 2016 | | Phase II trial of concurrent chemoradiotherapy with L-asparaginase and MIDLE chemotherapy for newly diagnosed stage I/II extranodal NK/T-cell lymphoma, nasal type (CISL-1008) | 정성현 |
| 2015 | | Phase II Trial of Nilotinib in Patients With Metastatic Malignant Melanoma Harboring KIT Gene Aberration: A Multicenter Trial of Korean Cancer Study Group (UN10-06). | 안미선 |
| 2012 | | Phase II trial of rituximab plus CVP combination chemotherapy for advanced stage marginal zone lymphoma as a first-line therapy: Consortium for Improving Survival of Lymphoma (CISL) study | 김효철 |
| 2017 | | Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia | 박준성 |
| 2007 | | Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non small-cell lung cancer. | - |
| 2013 | | Phase III, multicenter, randomized trial of maintenance chemotherapy versus observation in patients with metastatic breast cancer after achieving disease control with six cycles of gemcitabine plus paclitaxel as first-line chemotherapy: KCSG-BR07-02. | 강석윤 |
| 1997 | | Plasma tissue factor antigen levels in capillary whole blood and venous blood: effect of tissue factor on prothrombin time. | 김효철 |
| 2024 | | Prediction of Responsiveness to PD-L1/PD-1 Inhibitors Using miRNA Profiles Associated With PD-L1 Expression in Lung Adenocarcinoma and Squamous Cell Carcinoma | 고영화, 이현우, 한재호, 함석진 |
| 2013 | | Predictive factors for successful imatinib cessation in chronic myeloid leukemia patients treated with imatinib. | 박준성, 정성현 |
| 2012 | | Primary thyroid marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type: clinical manifestation and outcome of a rare disease - consortium for improving survival of lymphoma study | 정성현 |
| 2021 | | PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer | 최진혁 |
| 2021 | | Prognostic effects of cytokine levels on patients treated with taxane and zoledronic acid for metastatic breast cancer in bone (BEAT-ZO) (KCSG BR 10-13) | 강석윤 |
| 2012 | | Prognostic factors in primary diffuse large B-cell lymphoma of adrenal gland treated with rituximab-CHOP chemotherapy from the Consortium for Improving Survival of Lymphoma (CISL) | 정성현 |
| 2017 | | Prognostic impact of C-reactive protein/albumin ratio on the overall survival of patients with advanced nonsmall cell lung cancers receiving palliative chemotherapy | 고영화, 이현우 |
| 2017 | | Prognostic utility of FDG PET/CT and bone scintigraphy in breast cancer patients with bone-only metastasis | 강석윤, 안영실, 윤준기, 이수진, 임현이 |
| 2016 | | Prognostic Value of Axillary Nodal Ratio after Neoadjuvant Chemotherapy of Doxorubicin/Cyclophosphamide Followed by Docetaxel in Breast Cancer: A Multicenter Retrospective Cohort Study | 강석윤 |
| 2016 | | Prognostic value of negative interim 2-[(1)(8)F]-fluoro-2-deoxy-d-glucose PET/CT in diffuse large B-cell lymphoma | 강대용, 안영실, 윤준기, 이수진, 이현우, 정성현 |
| 2020 | | Quantitative analysis of tumor-specific BCL2 expression in DLBCL: refinement of prognostic relevance of BCL2 | 노진, 박준성, 정성현, 한재호 |
| 2016 | | Radiation Therapy-First Strategy After Surgery With or Without Adjuvant Chemotherapy in Stage IIIA-N2 Non-Small Cell Lung Cancer | 노오규, 박래웅, 박성용, 안미선, 오영택, 윤덕용, 이현우, 전미선, 최진혁, 허재성 |
| 2016 | | Radiation-related lymphopenia as a new prognostic factor in limited-stage small cell lung cancer | 노오규, 오영택, 이현우, 전미선, 조오연 |
| 2015 | | Ramosetron Versus Ondansetron in Combination With Aprepitant and Dexamethasone for the Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: A Multicenter, Randomized Phase III Trial, KCSG PC10-21. | 이현우 |
| 2020 | | Ramosetron versus Palonosetron in Combination with Aprepitant and Dexamethasone for the Control of Highly-Emetogenic Chemotherapy-Induced Nausea and Vomiting | 이현우 |
| 2019 | | Randomized Phase III Trial of Irinotecan Plus Cisplatin versus Etoposide Plus Cisplatin in Chemotherapy-Naive Korean Patients with Extensive-Disease Small Cell Lung Cancer | 최진혁 |
| 2019 | | S-1 Based Doublet as an Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer: Results from the Randomized Phase III POST Trial | 강석윤 |
| 2016 | | Selection of a mobilization regimen for multiple myeloma based on the response to induction therapy: granulocyte-colony stimulating factor (G-CSF) alone versus high-dose cyclophosphamide plus G-CSF | 박준성 |
| 2004 | | Sensory neural hearing loss after concurrent cisplatin and radiation therapy for nasopharyngeal carcinoma. | 강승희, 김철호, 오영택, 전미선, 최진혁 |
| 2012 | | Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial | 박준성 |
| 2021 | | Significance of descriptive symptoms and signs and clinical parameters as predictors of neuropathic cancer pain | 강석윤 |
| 2022 | | Significance of Single-cell Level Dual Expression of BCL2 and MYC Determined with Multiplex Immunohistochemistry in Diffuse Large B-Cell Lymphoma | 노진, 박준성, 정성현, 최윤석 |
| 2015 | | Strong immunoexpression of midkine is associated with multiple lymph node metastases in BRAFV600E papillary thyroid carcinoma. | 김장희, 박태준, 소의영, 이정훈, 최용원 |
| 2018 | | The 2016 WHO versus 2008 WHO Criteria for the Diagnosis of Chronic Myelomonocytic Leukemia | 박준성, 조성란, 한재호 |
| 2018 | | The Derived Neutrophil-to-Lymphocyte Ratio Is an Independent Prognostic Factor in Transplantation Ineligible Patients with Multiple Myeloma | 박준성, 정성현 |
| 2016 | | The Highest Metabolic Activity on FDG PET Is Associated With Overall Survival in Limited-Stage Small-Cell Lung Cancer | 박광주, 안영실, 오영택, 윤준기, 이수진, 최진혁 |
| 2019 | | The impact of primary tumor location in patients with metastatic colorectal cancer: a Korean Cancer Study Group CO12-04 study | 강석윤 |
| 1994 | | The treatment of lead poisoning from gunshot wounds with succimer (DMSA) | 김효철 |
| 2021 | | Trastuzumab-based palliative chemotherapy for HER2-positive gastric cancer: a single-center real-world data | 강석윤, 김태환, 신승수, 안미선, 이현우, 조헌도, 최용원, 최진혁 |
| 2020 | | Treatment strategy and outcomes in locally advanced head and neck squamous cell carcinoma: a nationwide retrospective cohort study (KCSG HN13-01) | 최진혁 |
| 2016 | | Value of volume-based metabolic parameters for predicting survival in breast cancer patients treated with neoadjuvant chemotherapy | 강두경, 강석윤, 김지영, 김태희, 안영실, 윤준기, 임현이, 정용식, 한세환 |
| 1995 | | Variability of in vivo recovery of factor IX after infusion of monoclonal antibody purified factor IX concentrates in patients with hemophilia B. The Mononine Study Group. | 김효철 |
| 2001 | | Vascular endothelial growth factor in the serum of patients with non-small cell lung cancer: correlation with platelet and leukocyte counts. | 강승희, 김현수, 김효철, 남동기, 박광주, 오영택, 이이형, 임호영, 전미선, 최진혁, 황성철 |
| 2017 | | Vascular enhancement pattern of mass in computed tomography may predict chemo-responsiveness in advanced pancreatic cancer | 김진홍, 양민재, 유병무, 이현우, 황재철 |
| 2017 | | Young Age Is Associated with Increased Locoregional Recurrence in Node-Positive Breast Cancer with Luminal Subtypes | 강석윤, 임현이, 전미선, 정용식, 최진혁, 한세환 |
